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Essentials
• Correct duration of treatment after a first unprovoked venous thromboembolism (VTE) is unknown.
• We assessed when restarting anticoagulation was worthwhile based on patient risk of recurrent VTE.
• When the risk over a one-year period is 17.5%, restarting is cost-effective.
• However, sensitivity analyses indicate large uncertainty in the estimates.
Summary. Background: Following at least 3 months of anticoagulation therapy after a first unprovoked venous thromboembolism (VTE), there is uncertainty about the duration of therapy. Further anticoagulation therapy reduces the risk of having a potentially fatal recurrent VTE but at the expense of a higher risk of bleeding, which can also be fatal. Objective: An economic evaluation sought to estimate the long-term cost-effectiveness of using a decision rule for restarting anticoagulation therapy vs. no extension of therapy in patients based on their risk of a further unprovoked VTE. Methods: A Markov patient-level simulation model was developed, which adopted a lifetime time horizon with monthly time cycles and was from a UK National Health Service (NHS)/Personal Social Services (PSS) perspective. Results: Base-case model results suggest that treating patients with a predicted 1 year VTE risk of 17.5% or higher may be costeffective if decision makers are willing to pay up to £20 000 per quality adjusted life year (QALY) gained.
However, probabilistic sensitivity analysis shows that the model was highly sensitive to overall parameter uncertainty and caution is warranted in selecting the optimal decision rule on cost-effectiveness grounds. Univariate sensitivity analyses indicate variables such as anticoagulation therapy disutility and mortality risks were very influential in driving model results.
Conclusion: This rep

Introduction
Venous thromboembolism (VTE) is the development of a clot in the veins. The number of deaths from VTE in the UK each year is five times greater than deaths from breast cancer, AIDS and road traffic incidents combined [1] and the cost of managing VTE was estimated at around £640 million to the UK National Health Service (NHS) [2] . Although there are several risk factors that can provoke an initial VTE event (such as hormone intake, surgery, trauma, pregnancy and prolonged immobility), patients can suffer an initial VTE event without any known trigger (unprovoked) [3] [4] [5] . Patients with an unprovoked VTE have a much higher risk of VTE recurrence than patients whose index VTE event has an identifiable cause [6] . The UK National Institute of Health and Care Excellence (NICE) [7] and the American College of Chest Physicians (ACCP) [8] recommend at least 3 months anticoagulation therapy following a first unprovoked VTE event; after 3 months of anticoagulation therapy following a first unprovoked VTE event, there is clinical equipoise on whether to extend anticoagulation therapy [9] [10] [11] . Extending anticoagulation therapy reduces the risk of having a possible recurrent VTE fatality, but treatment increases the risk of bleeding, which can be fatal. Balancing the benefit and harm of further treatment requires the identification of risk of recurrent VTE and an optimal threshold of VTE risk above which recommending anticoagulation therapy is beneficial.
A previously developed prognostic model estimated an individual patient's risk of a further unprovoked VTE without treatment [12] . A decision rule was developed using this prognostic model to stratify patients' treatment strategies based on a threshold of VTE recurrence risk (e.g. 5% VTE recurrence risk at 1 year post-therapy). This study aims to evaluate the cost-effectiveness of a decision rule for restarting therapy in patients after a first unprovoked VTE. The prognostic model uses data from D-dimer testing 30 days after cessation of anticoagulation; however, this test is not currently part of routine practice. A systematic review did not uncover any economic evaluations using a decision rule in this patient group [12] .
Methods
Model population
The patient population comprised adult individuals having already completed at least 3 months of anticoagulation therapy in response to their first unprovoked VTE. An initial VTE was defined as unprovoked where there was no history in the previous 3 months of any of the following risk factors: major surgery, lower limb trauma, use of combined oral contraceptive pill or hormone replacement therapy, pregnancy, significant immobility or cancer.
Patients entered the model having already had their Ddimer level measured 30 days after stopping at least 3 months of anticoagulation therapy. Individual patients were generated from patient data (Recurrent VTE Collaborative Database) [13] ; standard deviation, 751.3). The individual's risk of a recurrent VTE within 12 months was then determined by inputting their newly created characteristics into the prognostic model risk equation (Table S1 ) [12] . The risk distribution of the simulated patients is given in Table S2 .
Model pathways and clinical events
The economic model compared a strategy of no therapy (usual care) with a number of decision rule strategies, where therapy was restarted if the predicted annual risk of VTE recurrence was equal to or greater than the given threshold risk ( Figure S1 ). For pragmatic reasons, the arbitrary but clinically relevant thresholds were explored in the analyses (1%, 3%, 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 22.5% and 25%) and a treat-all strategy was also included as a comparator. These specified VTE risks were used as different decision rule comparators (examples of patients' predicted risks are given in Table S3 ). No patients initially resumed anticoagulation therapy in the no decision rule comparator. The decision rule was applied at the starting point of the model only. Once the decision rule was applied, all the patients encountered the same potential pathways in all strategies (Fig. 1) , with their characteristics determining the probabilities of clinical events, costs and utilities.
In 1 month, an individual had the probability of experiencing one clinical event: death from other causes, recurrent VTE (non-fatal distal or proximal DVT; fatal or non-fatal PE), and fatal or non-fatal major bleeds (intracranial bleed, gastrointestinal bleed and other major bleeds). A recurrent VTE carried a risk of post-thrombotic syndrome (PTS).
Other cause mortality was dependent on the current age and gender of the patient and was taken from UK life tables [14] . The risk of recurrent VTE depended on a patient's characteristics, time spent in the model, previous history of a recurrent VTE event taking place in the model, and treatment status. A recurrent VTE could be a PE, distal DVT or proximal DVT. The type of recurrent VTE was assumed to be affected by an individual's initial VTE site. Once a patient suffered a recurrent VTE, they were put on anticoagulation therapy for life, with therapy cessation only occurring with a later major bleeding event. VTE events were assumed to incur a one-off quality of life reduction, with a proportion of surviving patients assumed to suffer from severe PTS for life.
The risk factors for a major bleed in the model were treatment status and an individual's age if on treatment. Major bleeds were split into 'gastrointestinal bleeds', 'intracranial bleeds' and 'other major bleeds'. All major bleeding events had short-term costs and quality of life decrements. In addition, an intracranial bleed was assumed to be associated with ongoing costs and a permanent quality of life decrement, along with a sustained increased lifetime risk of other cause mortality. For the 'other major bleeds' category, it was agreed by clinical consensus that this heterogenous category of bleeds should have the same costs and quality of life decrement as a gastrointestinal bleed, for model simplification purposes.
Any major bleeding event led to discontinuation of anticoagulation therapy. A recurrent VTE in a later cycle was assumed to restart therapy. It was assumed that there was no effect of anticoagulation therapy on VTE recurrence risk by 30 days after cessation of therapy.
Model type
A Markov patient-level simulation was developed in TreeAge 2014 (TreeAge software, Williamstown, MA, USA) to estimate the cost-effectiveness of using a decision rule for restarting anticoagulation therapy vs. no anticoagulation therapy (usual care) in patients with a first unprovoked VTE event. A Markov model was deemed appropriate as it can represent a clinical situation where patients move between health states over a long period of time. A patient-level simulation allows individual patients, each with a set of varying characteristics created from patient level data, to be assigned a risk of VTE recurrence. Patient characteristics and clinical events that affect subsequent risks were remembered in the model with tracker variables. The model was run with a large number of simulated patients (50 000) to account for interpatient variability.
A time cycle of 1 month was selected to represent an assumption that this reflects a period in which a single clinical event might occur. Costs, utilities and probabilities were transformed into monthly equivalents as per the length of the time cycle. A half cycle correction was applied to costs and effects. The base-case cost-utility analysis was undertaken from a UK National Health Service (NHS)/Personal Social Services (PSS) perspective and considered a lifetime horizon.
Clinical parameters
Parameter estimates and their sources are listed in Table 1 . The base-case scenario used warfarin as the anticoagulation therapy. The risk of a patient's first recurrent VTE off therapy was calculated using the prognostic model for up to 3 years post D-dimer measurement (30 days after cessation of initial therapy). Weak calibration statistics of the prognostic model after 3 years prompted the use of an annual constant risk for the first recurrent VTE event off therapy thereafter. [15] Annual risk of a further VTE event after a VTE recurrence was an average of values for patients with normal and elevated D-dimer levels, on and off therapy respectively, in the PREVENT trial [16] . 
Resource use and costs
Costs of therapy and clinical events were included in the model ( Table 1) . The cost of a D-dimer test was incurred by the decision rule strategies as the D-dimer information was needed to enact the decision rules. All costs were updated to 2012/2013 prices using the Hospital and Community Health Services (HCHS) Index [17] .
Quality of life
Quality of life (utility) values were assumed to be age related as they were entered into the model using EuroQol-5 Dimensions (EQ-5D) UK normative values [18] . As patients aged in the model, their utility score changed to reflect their updated quality of life for their age. Utility values for clinical events and being on warfarin therapy (Table 2) were multiplied by the age-specific utility to derive quality of life reductions for patients experiencing a clinical event and/or on warfarin therapy.
Assessment of cost-effectiveness
The sequential incremental analysis was designed to calculate the cost per quality-adjusted life year (QALY) gained for applying a decision rule vs. the next most effective option, applying the rules of dominance and extended dominance. Cost-effectiveness was assessed in relation to VTE, venous thromboembolism; PTS, post-thrombotic syndrome; PE, pulmonary embolism. *A 95% confidence interval is assumed to be AE0.2 of the mean. †a is the shape parameter and b is the scale parameter.
the National Institute for Health and Care Excellence (NICE) lower threshold of £20 000 per QALY, where a value of £20 000/QALY is judged to be cost-effective [19] . Strategies were compared by increasing effectiveness and incremental cost-effectiveness ratios (ICERs) were calculated from the difference in costs and effects between a decision rule strategy and the next best alternative. A strategy is said to be dominated if it is more expensive and less effective than a comparator. All costs and outcomes were discounted at the recommended 3.5% [20] .
Deterministic sensitivity analysis
To test the robustness of base-case results, a number of deterministic sensitivity analyses were run to determine the impact of changing key parameters on results.
1 The model time horizon was restricted to 3 years, corresponding to the length of time the VTE prognostic model is used [12] . 2 The utility of warfarin therapy was reduced from 0.997 to 0.950 to assess how greater disutility associated with anticoagulant treatment affects results. 3 The probability of death from a PE was increased to 30% because of uncertainty amongst clinical experts on the true value. 4 The model entry was restricted to patients aged 60 years and above, whose risk of bleeding on therapy is higher. 5 Sub-group analyses were undertaken for index PE patients and index DVT patients, as the sub-group of PE patients were at higher risk of recurrence and mortality. 6 Sub-group analyses were undertaken for male and female patients. 7 The lag time in days for D-dimer was adjusted from 30 days to 20 and 40 days, which changed the risk profile of the patients.
Probabilistic sensitivity analysis
Where available, data were input into the model as distributions to assess parameter uncertainty in the form of a probabilistic sensitivity analysis (PSA). The model was rerun with 10 000 simulations for each trial of 1000 simulated patients and the results expressed as cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs).
Results
Base case results
Under base-case assumptions, restarting warfarin therapy for patients with a predicted annual VTE recurrence risk of 25% gave the lowest cost per QALY of £1983 (Table 3) . However, resuming anticoagulation therapy for patients with a predicted annual VTE recurrence risk of 17.5% yielded the highest number of QALYs, while also being considered cost-effective with an ICER of £14 980/ QALY gained.
Probabilistic sensitivity analysis results
The PSA results demonstrate there is considerable uncertainty around the base-case results. The cost-effectiveness planes ( Figure S2-S8) show the large uncertainty in the QALY differences for all strategies. The majority of the cost-QALY difference values indicate all strategies to be more costly than treating no one, but many of the points were in the north-west quadrant, where a strategy is more expensive and less effective compared with treat no one (dominated). The CEACs, which compared the most cost-effective base case option (17.5%) against several strategies (10%,12.5%,15%, 20%, 22.5% and 25%), show that treating those with a 1-year VTE risk of 17.5% has a 44.8-73.3% probability of being cost-effective at a willingness to pay threshold of £20 000 per QALY gained ( Figure S9-S15) . The results highlight substantial parameter uncertainty, even if the calculated ICER point estimates for the base-case results appear to be cost-effective.
Deterministic sensitivity analysis results
Deterministic sensitivity scenario results are shown in Table 4 . These illustrate that some variables were pivotal in changing the direction of model results. Assuming a greater disutility of being on warfarin therapy permits the 22.5% and 25% threshold decision rule to be cost-effective.
Increasing the risk of death from PE had improved the cost-effectiveness of the lower risk decision rule strategies compared with no therapy, with the 12.5% decision rule strategy yielding an ICER of £11 129/QALY gained. The age profile of patients made a difference to results. Allowing for a patient population to be aged 60 years and above only (higher bleeding risk on anticoagulation) revealed the 22.5% threshold option and above to be a cost-effective option, with all other options not cost-effective. Likewise, model results were sensitive to a patient's type of index VTE event. All decision rule strategies of 10% and above were cost-effective when the patients' index event was a PE, reflecting the high-risk nature of such index events. By contrast, the 25% threshold was the only cost-effective option when the patient's index event was a DVT.
Adjusting the lag time had little effect on the cost-effectiveness of the results, except for the 15% decision rule; this was now cost-effective when the lag time was increased from 20 to 40 days. Having a male-only cohort meant the lowest threshold to be cost-effective was the 12.5%, whereas a female-only cohort restricted the lowest threshold to be cost-effective to 15%.
Discussion
Principal findings
The economic evaluation assessed the cost-effectiveness of utilizing a decision rule for the resumption of anticoagulation therapy in patients with a first unprovoked VTE.
The base-case results indicate that treating patients with a predicted 1-year VTE risk of 17.5% and above with warfarin could be cost-effective compared with the next most effective option. These VTE risk cut-off points for treatment were much higher than what is considered acceptable in the literature [21] .
However, PSA results suggest great caution must be applied when considering the base-case results. Above 25% of the iterations showed less QALYs in the restarting anticoagulation decision rule strategies compared with the not restarting anticoagulation therapy strategy ('treat no one'); the 17.5% decision rule was the optimal option in less than half the iterations when compared with the higher VTE risk thresholds in the CEACs.
Quality of life while on treatment and mortality risk were important determinants in the cost-effectiveness results. Incorporating a greater disutility when on warfarin therapy changes the results, with only the 22.5% and 25% of VTE risk threshold options remaining costeffective. Meanwhile, a small change in the proportion of PEs that result in death makes restarting anticoagulation therapy at 12.5% even more cost-effective.
Focusing on different subcategories of patients also changes the base-case results. Sensitivity analyses suggest that all index PE patients with a predicted VTE recurrence risk of 10% and above should be treated with lifelong anticoagulation therapy, probably because these patients were assumed to have a higher risk of a recurrent VTE that would be a PE. Conversely, for index DVT patients, the only restart anticoagulation option favoured on cost-effectiveness grounds is a 1-year recurrent VTE risk of 25% or higher. The impact of higher risks of bleeding as a result of anticoagulation therapy in the older patient population aged 60 years and above was not offset by the reduced risk of recurrent VTE at the lower risk threshold strategies.
Strengths and weaknesses of the analysis
This is the first economic evaluation to consider using a decision rule to weigh up the advantages and disadvantages of resuming anticoagulation treatment in unprovoked VTE patients. A key strength of the analysis is the use of an individual patient simulation that allows a personalized risk prediction for hypothetical patients with characteristics drawn from real patient data. This was preferable to the more common cohort model with a homogenous set of characteristics, as the model results were more representative of a realistic patient population. The modelling method lessened the need for a multitude of separate health states because the Markovian lack of memory assumption encountered in cohort models was overcome by tracker variables.
Several simplifying assumptions were needed. The prognostic model used to calculate individual risk predictions was applied at 30 days after cessation of anticoagulation therapy, which is not clinically ideal because some patients will have recurrence in these 30 days. This was a result of D-dimer measurements being included within the prognostic model as an important predictor improving model discrimination, and therefore stratification of patients into high and low-risk groups (as in the decision rule examined here) [12] . D-dimer measurements were only available after cessation of therapy in the original dataset; however, there is much interest and potential benefit in the use of D-dimer measurements on therapy as a predictor of VTE recurrence [22] . Indeed, this would allow immediate treatment decisions to be made before cessation of therapy, potentially negating the small number of possible recurrent events in the 30-day window from cessation of therapy to use of the decision rule evaluated here. The model does not include pulmonary hypertension, which could be considered a further limitation, and its inclusion may lower the risk threshold for treatment.
In the absence of data, constant risks of VTE recurrence were used beyond 3 years, after a subsequent VTE and when on treatment. In practice, risk of recurrent VTE is likely to vary by patient characteristics. Additionally, the use of the prognostic model for the economic analysis implicitly assumes that the risk prediction tool is perfectly accurate. However, there will be a degree of error between predictions and reality. For example, the prognostic model was derived from patientlevel trial data and there is an inherent selectivity of patients in trials (e.g. fewer co-morbidities). In addition, the course of action on the resumption and cessation of anticoagulation after a major bleeding event may differ between patients. In truth, some patients may continue with their anticoagulation therapy after a major bleed, whereas others who subsequently go on to suffer a VTE may not restart anticoagulation because of their high risk of bleeding. Only a healthcare perspective was considered in this model, in line with UK national guidance, where threshold values of cost-effectiveness are available (£20 000 to £30 000 per QALY) [19] . Cost-effectiveness may differ when using the societal perspective, but it would be difficult to determine in what direction. Although patientincurred costs would be higher with treatment with lifelong anticoagulation as a result of visits for INR tests, productivity losses may be higher where there is a higher risk of clinical events, such as DVT, PE and bleeds, or if anticoagulation is required because of a further thrombotic event.
Future research
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